Blood tests could predict survival odds for patients with metastatic cancer
By measuring the proportion of DNA in the bloodstream that comes from a tumor, liquid biopsies may be able to guide treatment discussions
06-Dec-2022 - As cancers grow and potentially spread to new parts of the body, they often shed cells and DNA into the blood stream. DNA can be analyzed for both the amount of DNA present and whether any potential mutations exist that may aid providers in deciding on treatments. These tests, known as liquid ...
Moss repair team also works in humans
"If we could correct faulty sites in the genetic code with RNA editing methods, this would potentially also offer starting points for the treatment of hereditary diseases"
21-Sep-2022 - If everything is to run smoothly in living cells, the genetic information must be correct. But unfortunately, errors in the DNA accumulate over time due to mutations. Land plants have developed a peculiar correction mode: they do not directly improve the errors in the genome, but rather ...
How the most common DNA mutation happens
05-Feb-2018 - Researchers describe how two normally mismatched bases in human DNA, guanine and thymine, are able to change shape in order to form an inconspicuous rung on the helical DNA "ladder." This allows them to survive by avoiding the body's natural defenses against genetic mutations. "When these two ...
Exonhit to Acquire Redpath Integrated Pathology, Inc.
Complementary fit between RedPath’s DNA platform and ExonHit’s RNA platform
27-Apr-2010 - ExonHit Therapeutics S.A. announced that it entered into a binding agreement for the acquisition of RedPath Integrated Pathology, Inc., a privately held molecular diagnostics company, focused on cancer. RedPath will become part of ExonHit’s US operations. Headquartered in Pittsburgh, ...
Link Technologies secures exclusive license for ultra sensitive diagnostic probes
Deal marks the start of ongoing collaboration between Link and The University of Manchester
01-Dec-2009 - Link Technologies Ltd has announced an exclusive license deal with The University of Manchester Intellectual Property Limited (UMIP). Under the terms of the license for the University’s “exciplex” technology, Link will manufacture and sell highly sensitive exciplex-based diagnostic reagents ...
Haven't found the right news yet?
The analytica-world.com news search
Start your targeted search now with a wide range of filter options. Our database includes an archive of 6,716 lab and analytics news from business and science, which you can search by topic and organization, filtered by time and geography.